Phase 3 N=46 Cytokine Removal in Cardiopulmonary Bypass Patients
Elective Cardiac Surgical Interventions
Primary: IL-6 — 0; 0; 0; 0 pg/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=119 Exercise and Inflammation in the Elderly
Inflammation · Insulin Sensitivity
Primary: Insulin Sensitivity — 50.2; 40.7; 57.5; 42.3 μmol/kgFFM/min
N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
N/A N=25 Diet and Systemic Inflammation
Low-grade Chronic Inflammation · Intestinal Permeability · Type 2 Diabetes Mellitus
Primary: Fasting Plasma C-reactive Protein — 0.91; 1.07; 1.67; 1.09 mg/L — p=0.403
N/A N=21 Inflammatory Cytokine Quantification in Infants
Sepsis · Congenital Diaphragmatic Hernia · Neonatal Cardiopulmonary Failure
Primary: TNF-alpha, Baseline — 8.88 pg/mL
N/A N=100 Inflammation and the Metabolic Syndrome in Humans
Metabolic Syndrome X
Primary: The Primary Outcome Measure is Plasma Levels of TNF Alpha. — 507 ng/mL
N/A N=22 Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients
End Stage Renal Disease
Primary: High Sensitivity C-reactive Protein (hsCRP) — 4.67; 15.11 mg/dl — p=0.008
Phase 2 N=12 Blood Lipopolysaccharide (LPS) Rifaximin Study
Obese · Insulin Resistance · Metabolic Syndrome
Primary: Circulating LPS — 2.44; 1.86; 13.66; 10.00 EU/mL — p=>0.05
N/A N=141 Anti-inflammatory Effect of Therapeutic Hypothermia in Out-hospital Cardiac Arrest Patients With Cardiogenic Shock
Cardiac Arrest
Primary: Survival Rate - Number of Participants Alive — 55; 20; 32; 34 Participants — p=<0.001
Phase 1 N=70 Inflammatory Markers in Trauma Patient Outcomes
Polytrauma
Primary: Length of Hospital Stay — 7; 8 days — p==0.275
Phase 1 N=12 Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects
Arthritis, Rheumatoid
Primary: Part 1: Change From Baseline Primary Soluble Inflammatory Mediators in Blood: Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL) 6 for LPS Arm — 2.4086; 0.2798…
N/A N=17 Cytokines in Papillon-Lefèvre Syndrome
Papillon-Lefevre Disease
Primary: Serum Concentrations of Interleukin (IL)-1 Beta — 1100.00; 896.21; 65559; 45734 pg/ml
N/A N=38 Local and Systemic Antimicrobials in Non-surgical Periodontal Therapy
Periodontitis
Primary: Change in Pocket Probing Depth (PPD) — 3.932; 4.082; 3.253; 3.294 mm
Phase 3 N=458 Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)
Atrial Fibrillation
Primary: Postoperative Atrial Fibrillation — 27.2; 27.8; 25.9 percentage of patients — p=0.95
Phase 2 N=167 Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury
Acute Lung Injury · Sepsis
Primary: Modified Change in Sequential Organ Failure Assessment (mSOFA) Score — -2.96; -3.20 score on a scale
Phase 3 N=500 Supplemental Enteral Protein in Critical Illness
Nutrition Disorder · Trauma · Critical Illness
Primary: Serum Concentrations of Transthyretin at 3 Weeks After Injury. — 18.1; 18.9 mg/dl
Phase 2 N=20 An Inflammatory Challenge Using Endotoxin
Alcohol Use Disorder · Inflammatory Response · Craving
Primary: Cue-induced Craving — 4.5004; 7.9081; 4.5004; 5.6178 score on a scale — p=0.036
N/A N=73 Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS
Sepsis
Primary: Delta Curve Between Calculated GFR and GFR Measured by Iohexol at Baseline — 91.5; 88.3; 93.6; 90.0 ml/min/1.73m2 — p=<0.05
Phase 3 N=20 Sitagliptin Therapy and Kinetics of Inflammatory Markers
Type 2 Diabetes Mellitus
Primary: Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period
Phase 2 N=31 Interleukin-1 Blockade in HF With Preserved EF
Heart Failure With Normal Ejection Fraction
Primary: Change in Aerobic Exercise Capacity — -0.2; 1.0 ml/kg/min
N/A N=26 Mechanistic Inflammatory Sub-study Embedded Within the Albumin vs Balanced Crystalloid Trial
Sepsis
Primary: Longitudinal Change Over Time in Cell Types and Pro and Anti Inflammatory Cytokines in Sepsis. — 14; 12 participants
N/A N=25 Mechanisms of Insulin Resistance in Humans
Inflammation · Insulin Resistance
Primary: Insulin Signaling With Lipid Infusion — 0.4334; 0.7276; 0.5264; 0.3534 ratio
N/A N=39 Anti-Inflammatory Treatment of Schizophrenia
Schizophrenia
Primary: Change in Persistent Positive Symptoms — 13; 14; 14; 14 units on a scale
N/A N=62 Procalcitonin Levels in Patients With Fever and a Central Line
Fever
Primary: Procalcitonin Level at ED Presentation — 18.47; 0.65 ng/dL — p=0.001
N/A N=226 Utility of Presepsin in Distinguishing Between Sepsis and SIRS
SIRS · Sepsis
Primary: Area Under the Receiver Operating Characteristic Curve (ROC-AUC) of the Plasma Presepsin Concentration for Discriminating Between SIRS and Sepsis — 0.7218; 0.6901…
Phase 2 N=56 Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants
Complication Due to Immunization
Primary: The Change in the Number of CRE (Extracted From Printed Monitoring Tracings Compared to Noted Nurses' Surveillance) Following the First Dose of Pentavalent Vaccine in…
N/A N=43 Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
N/A N=64 Effect of Inflammation on Pharmacokinetics of Posaconazole
Mycoses
Primary: C Reactive Protein Levels in mg/L (CRP) on Posaconazole Concentrations in mg/L — 1.8; 23.5 mg/L — p=0.77
N/A N=24 Markers of Inflammation and Lung Recovery in ECMO Patients for PPHN
Persistent Pulmonary Hypertension of the Newborn
Primary: CD16/41 — 1.90; 1.13 percent change
Phase 2 N=45 Targeting Inflammation to Treat Cardiovascular Aging
Vascular Stiffness · Endothelial Dysfunction · Diastolic Dysfunction
Primary: Carotid-femoral Pulse Wave Velocity (CFPWV) — 831.3; 785.1; 538.0; 839.6 cm/sec